Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Cardiology Department, Emergency Clinical Hospital Bucharest, 014461 Bucharest, Romania.
Int J Environ Res Public Health. 2022 Jul 28;19(15):9250. doi: 10.3390/ijerph19159250.
Objectives: There are limited epidemiological data regarding atrial fibrillation (AF) in hypertensive (HT) Romanian adults. We sought to evaluate AF prevalence trends in the SEPHAR surveys (Study for Evaluation of Prevalence of Hypertension and Cardiovascular Risk in an Adult Population in Romania) during a nine-year interval (2012−2016−2021). Methods: Three consecutive editions of a national epidemiological survey regarding HT included representative samples of subjects stratified by age, gender and area of residence (SEPHAR II-IV—in total, 5422 subjects, mean age 48.69 ± 16.65 years, 57.5% (n = 3116) females). A post-hoc analysis of AF prevalence and oral anticoagulation (OAC) rates was performed. AF definition was based on a documented medical history of AF and/or AF documentation by study electrocardiogram. Results: General AF prevalence was 5.5% (n = 297). AF prevalence in HT subjects was 8.9% (n = 209) and has risen since SEPHAR II—7.2% (n = 57) and SEPHAR III—8.1% (n = 72) to SEPHAR IV—11.8% (n = 80), respectively (p = 0.001). AF prevalence has increased in HT males (SEPHAR II—5.3% (n = 19), SEPHAR III—7.6% (n = 26) and SEPHAR IV—11.7% (n = 35) (p = 0.010)) and in HT from urban areas (SEPHAR II—7.8% (n = 37), SEPHAR III—7.8% (n = 40), SEPHAR IV—14.7% (n = 50), p < 0.001). In SEPHAR III-IV, only 19.3% (n = 23) of HT AF patients with OAC indication were anticoagulated. Conclusions: AF prevalence has increased by ~64% in hypertensive Romanian adults between 2012 and 2021. However, anticoagulation strategies may be suboptimal in patients with cardioembolic risk.
罗马尼亚高血压成年人的心房颤动(AF)的流行病学数据有限。我们旨在评估 SEPHAR 调查(罗马尼亚成年人高血压和心血管风险评估研究)在九年期间(2012-2016-2021)的 AF 患病率趋势。
对三项全国性高血压流行病学调查的连续版本进行分析,这些调查包括按年龄、性别和居住地区分层的代表性样本(SEPHAR II-IV-共 5422 名受试者,平均年龄 48.69±16.65 岁,57.5%(n=3116)为女性)。对 AF 患病率和口服抗凝剂(OAC)率进行了事后分析。AF 的定义基于 AF 的书面病史和/或研究心电图的 AF 记录。
总的 AF 患病率为 5.5%(n=297)。高血压患者的 AF 患病率为 8.9%(n=209),自 SEPHAR II(7.2%(n=57))、SEPHAR III(8.1%(n=72))以来有所上升,至 SEPHAR IV(11.8%(n=80))(p=0.001)。高血压男性的 AF 患病率(SEPHAR II(5.3%(n=19))、SEPHAR III(7.6%(n=26))和 SEPHAR IV(11.7%(n=35)))(p=0.010))和城市地区的高血压患者(SEPHAR II(7.8%(n=37))、SEPHAR III(7.8%(n=40))、SEPHAR IV(14.7%(n=50))(p<0.001))有所增加。在 SEPHAR III-IV 中,仅有 19.3%(n=23)具有 OAC 适应证的高血压 AF 患者接受了抗凝治疗。
2012 年至 2021 年期间,罗马尼亚高血压成年人的 AF 患病率增加了约 64%。然而,在有栓塞风险的患者中,抗凝策略可能并不理想。